A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterationsMargaret C. Wheless, Kristen K. Ciombor, Olumide B. Gbolahan et al.|The Oncologist|2025Cited by 3
New Frontiers in the Treatment of Rectal CancerCeline Yeh, Andrea Cercek, Margaret C. Wheless et al.|Annual Review of Medicine|2025Cited by 1